AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00705380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents
Description: CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
Study NCT00705380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control
Description: During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
Study NCT01213511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting with the use of minimal extracorporeal circulation
Description: The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
Study NCT01213511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting under conventional extracorporeal circulation
Description: A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
Study NCT03692195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WHOOP Strap 2.0
Description: The WHOOP Strap 2.0 is worn on the wrist, continuously throughout the 7-day period of which participants will be assigned. It measures heart rate, sleep, strain, and recovery.
Study NCT03692195 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Device
Description: The WHOOP Strap 2.0 is not worn on the wrist for a seven day period.
Study NCT03477344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
Study NCT03477344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
Study NCT04065815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week
Study NCT04065815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-EMS
Description: Whole-Body Electromyostimulation (WB-EMS):~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training:~* Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week
Study NCT04065815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Description: HIIT:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT):~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 2 training sessions per week
Study NCT04065815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined HIIT and Resistance Training (Combi)
Description: HIIT combined with conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program:~HIIT:~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 1 training session per week~Resistance Training:~* five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 1 training session per week
Study NCT01557127 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
Study NCT00717132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based behavior modification
Description: Family-base behavior treatment for obesity. Children and parents meeting together for 15 total behavioral modification intervention sessions.
Study NCT04165447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-pack labeling strategy
Description: We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.
Study NCT00249912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and rosuvastatin
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Study NCT03851705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran Sodium for injection
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Study NCT00249912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and rosuvastatin
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Study NCT03851705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% sodium chloride in water for injection)
Study NCT03851705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Sterile normal saline (0.9% sodium chloride in water for injection)
Study NCT01486732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Infusion
Description: The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
Study NCT00868972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous renal stenting intervention
Description: Percutaneous renal stenting intervention
Study NCT01486732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
Study NCT01486732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
Study NCT01486732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Umbilical Cord Blood
Description: Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
Study NCT00692341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
Study NCT00868972 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous renal stenting intervention
Description: Percutaneous renal stenting intervention
Study NCT00868972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distal embolic protection
Description: Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
Study NCT02346903 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capsaicin
Description: one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
Study NCT01734798 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT00821353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RF catheter ablation
Description: RF catheter ablation
Study NCT00821353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drugs
Description: One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
Study NCT01695265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercie oronasal breathing (ONB)
Description: 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using oronasal breathing (ONB)
Study NCT01695265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercie nasal breathing through the FB
Description: Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using FeelBreathe device (FB)
Study NCT05017766 — intervention group
Intervention type: OTHER
Intervention: analysis of antimicrobial resistance
Description: In samples from patients infected with one of the focus pathogens (E. coli, Klebsiella species, S. aureus, P. aeruginosa) will be:~(i) isolated and pathogenic bacteria characterized; (ii) pathogen in-situ properties at single-cell and bulk average determined; (iii) human metabolites, proteins and cells determined (iv) antibiotic concentration determined (v) bacterial growth monitored~Deducted from the data will be:~1. relevant human components and pathogen properties that are common to most patients with similar indication~2. underlying regulatory networks and triggers in pathogen cells and human tissues.~Clinical outcomes (survival/mortality) and treatment response (response or failure) will be correlated to the in vitro retrieved host and bacterial data.
Study NCT04318795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive spinal decompression (MIS-D)
Description: lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
Study NCT04318795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive spinal decompression and fusion (MIS-TLIF)
Description: lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
Study NCT00877253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM 220mg/㎡, Carboplatin 5AUC
Description: Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
Study NCT00877253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM 260mg/㎡, Carboplatin 5AUC
Description: Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
Study NCT00877253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM 300mg/㎡, Carboplatin 5AUC
Description: Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
Study NCT04691726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 10mg/ml
Description: bolus i.v. + continuous i.v. infusion
Study NCT04691726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: bolus i.v. + continuous i.v. infusion
Study NCT04691726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole
Description: 2,5 g i.v. BD
Study NCT01734798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Study NCT01734798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy and Drug
Study NCT02342847 — intervention group
Intervention type: OTHER
Intervention: N/A (non-interventional study)
Study NCT03333928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTD1801
Description: HTD1801 tablets, 250 mg
Study NCT03333928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets manufactured to mimic HTD1801 tablets
Study NCT03358355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unacelyated ghrelin
Description: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.
Study NCT00249912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Study NCT02936362 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Consumption of sourdough bread
Description: Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
Study NCT04691726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metamizole
Description: 2,5 g i.v. BD
Study NCT02936362 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Consumption of white bread
Description: Participants will be given white bread to consume instead of other wheat products. 110g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
Study NCT04691726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: continuous i.v. infusion adjusted to VAS scale score
Study NCT04691726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: continuous i.v. infusion adjusted to VAS scale score
Study NCT02026115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAINReportIt
Description: PAINReportIt is a software program first developed with an electronic MPQ (1970 version) and now includes questions about analgesics used by the patient and a shortened version of the pain Barriers Questionnaire (BQ). PAINReportIt is designed as an interactive, touch screen method for assessment of pain. It can be self-administered and requires little or no patient computer experience and minimal or no provider time for administration. Directions for self-administration allow the patient to read instructions on-screen and practice making all types of selection responses that are available in the program. Directions from the paper and pencil tools were modified to address the touch screen method of recording patient responses. The copyright is owned by Dr. Ronald Melzack for the MPQ and Dr. Sandra Ward for the BQ. Both of these individuals have authorized the modifications, presentation format, and computerized use of their tools.
Study NCT02026115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAINReportIt
Description: PAINReportIt is a software program first developed with an electronic MPQ (1970 version) and now includes questions about analgesics used by the patient and a shortened version of the pain Barriers Questionnaire (BQ). PAINReportIt is designed as an interactive, touch screen method for assessment of pain. It can be self-administered and requires little or no patient computer experience and minimal or no provider time for administration. Directions for self-administration allow the patient to read instructions on-screen and practice making all types of selection responses that are available in the program. Directions from the paper and pencil tools were modified to address the touch screen method of recording patient responses. The copyright is owned by Dr. Ronald Melzack for the MPQ and Dr. Sandra Ward for the BQ. Both of these individuals have authorized the modifications, presentation format, and computerized use of their tools.
Study NCT02026115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAINConsultN
Description: PAINConsultN for hospice nurses. Our previous studies support the feasibility and clinical effect of PAINConsultN. This narrative and graphic tool provides decision support for the nurse's clinical decisions regarding management of the patient's pain. Based on the PAINReportIt output and published cancer pain guidelines, PAINConsultN generates an algorithm-based consultation report with a list of recommendations that could be useful to provide improved pain relief. If the patient's PAINReportIt output indicates the pain level is consistent with the patient's goals for pain management and represents no pain or a mild pain level, the consultation report acknowledges the therapy plan and reinforces its consistency with pain guidelines.
Study NCT02026115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAINUCope
Description: We tested the prototype of the PAINUCope component of the intervention in three completed studies. PAINUCope is a multimedia, computer generated tool that provides tailored patient information to overcome their misconceptions about pain and to help them engage in self-care activities that contribute to reducing their pain. PAINUCope focuses on two crucial aspects of pain management: 1) reporting cancer pain; and 2) safe and effective use of pain medicines. All the educational materials were written at a 6th grade reading level and presented as 21st Century best-practices, evidence-based facts or scripts for the person living with cancer or sickle cell disease (in one study). The facts or scripts are customized to the patient's need for this type of health information. The patient's responses on PAINReportIt govern the specific health information that is shared with the patient via PAINUCope.
Study NCT01103830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurartesim™
Description: 3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
Study NCT04050475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: The Fasting Mimicking Diet is a low-calorie, five-day eating program meant to promote weight loss and provide the same benefits as more traditional fasting methods.
Study NCT01596868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and cisplatin
Description: Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
Study NCT01596868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and cisplatin
Description: Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.